Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs VNET Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while VNET Group Inc trades at $7.7 (market cap $2.28B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 17.5× VNET Group Inc's market cap. Which is the better fit depends on your goals.
| ALNY | VNET | |
|---|---|---|
Market Cap | $39.89B | $2.28B |
Sector | Health | Technology |
52-Week High | $491.22 | $14.03 |
52-Week Low | $278.09 | $7.34 |
Enterprise Value | $38.15B | $5.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VNET trades at $8.01, down 0.5% with bearish technical signals. The company reported Q1 2026 revenue growth driven by AI demand but posted a significant net loss of $1.20 per share, missing estimates. Analyst sentiment remains positive with 62.5% buy ratings and a 54% upside target. Recent strategic investments and leadership changes signal transformation amid ongoing profitability challenges.
The outlook balances strong AI-driven revenue potential against persistent profitability concerns. Investment opportunity lies in market share gains from AI infrastructure demand, while risks include negative margins, class action litigation, and execution challenges during leadership transition. The stock faces near-term pressure from consecutive earnings misses despite long-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
